Treatment of acute exacerbations of COPD

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Chronic obstructive pulmonary disease (COPD), the fourth leading cause of death in the United States, is increasing worldwide and is projected to be the third leading cause of death in the United States by the year 2020 (1). It affects nearly 16 million Americans, and more than $18 billion is spent annually on medications, physician visits, and hospitalizations. COPD is characterized by chronic airflow obstruction with episodic acute exacerbations, which result in increased morbidity and mortality. Patients hospitalized with exacerbations have an overall mortality rate of 3% to 4%, and up to 24% of patients requiring care in the intensive care unit die (2). Since forced expiratory volume in 1 second correlates closely with life expectancy and exacerbation rate, early diagnosis (through spirometric testing) and prevention may reduce acute exacerbations and health care costs.

Original languageEnglish (US)
Pages (from-to)28-36
Number of pages9
JournalClinical Cornerstone
Volume5
Issue number1
DOIs
StatePublished - Jan 1 2003

Fingerprint

Chronic Obstructive Pulmonary Disease
Cause of Death
Mortality
Forced Expiratory Volume
Life Expectancy
Health Care Costs
Intensive Care Units
Early Diagnosis
Patient Care
Hospitalization
Therapeutics
Morbidity
Physicians

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Treatment of acute exacerbations of COPD. / Blanchard, Amy R.

In: Clinical Cornerstone, Vol. 5, No. 1, 01.01.2003, p. 28-36.

Research output: Contribution to journalArticle

@article{2d6f98703d1441efb6bf9a16930db003,
title = "Treatment of acute exacerbations of COPD",
abstract = "Chronic obstructive pulmonary disease (COPD), the fourth leading cause of death in the United States, is increasing worldwide and is projected to be the third leading cause of death in the United States by the year 2020 (1). It affects nearly 16 million Americans, and more than $18 billion is spent annually on medications, physician visits, and hospitalizations. COPD is characterized by chronic airflow obstruction with episodic acute exacerbations, which result in increased morbidity and mortality. Patients hospitalized with exacerbations have an overall mortality rate of 3{\%} to 4{\%}, and up to 24{\%} of patients requiring care in the intensive care unit die (2). Since forced expiratory volume in 1 second correlates closely with life expectancy and exacerbation rate, early diagnosis (through spirometric testing) and prevention may reduce acute exacerbations and health care costs.",
author = "Blanchard, {Amy R}",
year = "2003",
month = "1",
day = "1",
doi = "10.1016/S1098-3597(03)90006-8",
language = "English (US)",
volume = "5",
pages = "28--36",
journal = "Clinical Cornerstone",
issn = "1098-3597",
publisher = "Excerpta Medica",
number = "1",

}

TY - JOUR

T1 - Treatment of acute exacerbations of COPD

AU - Blanchard, Amy R

PY - 2003/1/1

Y1 - 2003/1/1

N2 - Chronic obstructive pulmonary disease (COPD), the fourth leading cause of death in the United States, is increasing worldwide and is projected to be the third leading cause of death in the United States by the year 2020 (1). It affects nearly 16 million Americans, and more than $18 billion is spent annually on medications, physician visits, and hospitalizations. COPD is characterized by chronic airflow obstruction with episodic acute exacerbations, which result in increased morbidity and mortality. Patients hospitalized with exacerbations have an overall mortality rate of 3% to 4%, and up to 24% of patients requiring care in the intensive care unit die (2). Since forced expiratory volume in 1 second correlates closely with life expectancy and exacerbation rate, early diagnosis (through spirometric testing) and prevention may reduce acute exacerbations and health care costs.

AB - Chronic obstructive pulmonary disease (COPD), the fourth leading cause of death in the United States, is increasing worldwide and is projected to be the third leading cause of death in the United States by the year 2020 (1). It affects nearly 16 million Americans, and more than $18 billion is spent annually on medications, physician visits, and hospitalizations. COPD is characterized by chronic airflow obstruction with episodic acute exacerbations, which result in increased morbidity and mortality. Patients hospitalized with exacerbations have an overall mortality rate of 3% to 4%, and up to 24% of patients requiring care in the intensive care unit die (2). Since forced expiratory volume in 1 second correlates closely with life expectancy and exacerbation rate, early diagnosis (through spirometric testing) and prevention may reduce acute exacerbations and health care costs.

UR - http://www.scopus.com/inward/record.url?scp=0037266525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037266525&partnerID=8YFLogxK

U2 - 10.1016/S1098-3597(03)90006-8

DO - 10.1016/S1098-3597(03)90006-8

M3 - Article

C2 - 12739309

AN - SCOPUS:0037266525

VL - 5

SP - 28

EP - 36

JO - Clinical Cornerstone

JF - Clinical Cornerstone

SN - 1098-3597

IS - 1

ER -